Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system
Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system
复制标题
DOI：
10.1016/s0885-3924(96)00274-6
复制
发表时间：
1997-02-01
影响因子：
4.7
通讯作者：
Kaplan, E
中科院分区：
文献类型：
--
作者：
Yellen, SB;Cella, DF;Kaplan, E
本文报告了使用 28 个项目评估癌症患者疲劳和贫血相关问题的调查问卷的开发和验证。以癌症治疗功能评估 - 一般 (FACT-G) 问卷为基础，制定了 20 个与贫血患者的症状和担忧相关的附加问题。这 20 个问题中有 13 个问题涉及疲劳，其余 7 个问题涉及与贫血相关的其他问题。通过对 14 名贫血肿瘤患者和 5 名肿瘤学专家进行半结构化访谈，制作了两种工具：FACT-疲劳 (FACT-F)，由 FACT-G 加 13 个疲劳项目组成；FACT-贫血 (FACT-An)，由 FACT-F 加 7 个非疲劳项目组成。这些测量结果又在 50 名血红蛋白水平在 7 至 15.9 g/dL 之间的癌症患者的第二个样本中进行了测试。 41 项 FACT-F 和 48 项 FACT-An 分数被发现稳定（两者的重测 r = 0.87）且内部一致（系数 alpha 范围 = 0.95-0.96）。症状特异性分量表也表现出良好的稳定性（重测r范围= 0.84-0.90），疲劳分量表表现出很强的内部一致性（系数α范围= 0.93-095）。各种非疲劳项目的内部一致性较低，但可以接受（α范围 = 0.59-0.70），特别是考虑到它们与患者评估的体能状态和血红蛋白水平密切相关。收敛和判别效度测试显示，与其他已知的疲劳指标有显着的正相关关系，与活力有显着的负相关关系，并且与社会期望值缺乏关系。两种量表的总分根据血红蛋白疲劳水平 (p < 0.05) 和患者评估的表现状态 (p < 0.0001) 来区分患者。 FACT-F 的 13 项疲劳分量表和 FACT-An 的 7 项非疲劳项目还根据血红蛋白水平 (p < 0.05) 和患者评定的体能状态 (p 小于或等于 0.001) 来区分患者。 FACT-F 和 FACT-An 是癌症治疗中生活质量的有用衡量标准，使人们更加关注疲劳和贫血问题。疲劳分量表也可以单独作为一个非常简短的分量表；而是可靠且有效的疲劳测量。 (C) 美国癌症疼痛缓解委员会，1997 年。
This paper reports the development and validation of a questionnaire assessing fatigue and anemia-related concerns in people with cancer Using the 28-item. Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire as a base, 20 additional questions related to the symptoms and concerns of patients with anemia Were developed. Thirteen of these 20 questions dealt with fatigue, while the remaining 7 covered other concerns related to anemia. Using semi-structured interviews with 14 anemic oncology patients and 5 oncology experts, two instruments were produced: The FACT-Fatigue (FACT-F), consisting of the FACT-G plus 13 fatigue items, and the FACT-Anemia (FACT-An), consisting of the FACT-F plus 7 nonfatigue items. These measures were, in turn, tested on a second sample of 50 cancer patients with hemoglobin levels ranging from 7 to 15.9 g/dL. The 41-item FACT-F and the 48 item FACT-An scores were found to be stable (test-retest r = 0.87 for both) and internally consistent (coefficient alpha range = 0.95-0.96). The symptom-specific subscales also showed good stability (test-retest r range = 0.84-0.90), and the Fatigue subscale showed strong internal consistency (coefficient alpha range = 0.93-095). Internal consistency of the miscellaneous nonfatigue items was lower but acceptable (alpha range = 0.59-0.70), particularly in light of their strong relationship to patient-rated performance status and hemoglobin level. Convergent and discriminant validity testing revealed a significant positive relationship with other known measures of fatigue, a significant negative relationship with vigor and a predicted lack of relationship with social desirability. The total scores of both scales differentiated patients by hemoglobin fatigue level (p < 0.05) and patient-rated performance status (p < 0.0001). The 13-item Fatigue subscale of the FACT-F and the 7 nonfatigue items of the FACT-An also differentiated patients by hemoglobin level (p < 0.05) and patient-rated performance status (p less than or equal to 0.001). The FACT-F and FACT-An are useful measures of quality of life in cancer treatment, adding more focus to the problems of fatigue and anemia. The Fatigue Subscale may also stand alone as a very brief; but reliable and valid measure of fatigue. (C) U.S. Cancer Pain Relief Committee, 1997.